Stock Analiz

Standard Biotools Inc. LAB

Biotechnology: Laboratory Analytical Instruments · IPO 2011 · data as of November 13, 2026

$0.71Market cap $279M
Open the interactive analysis →

Standard Biotools Inc. (LAB) is a industrial company listed in the US with a market value of about $279M. In the twelve months to September 30, 2026 it had revenue of $84M and net income of $133M, a net margin of 157.6%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 2.1, 5-year revenue growth of -9% a year, a 5-year average ROIC of -154%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 82% below the current price.

About Standard Biotools

Standard Biotools is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2011. Revenue went from $116M in 2014 to $85M in 2025, a decline of about 2.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 387% over three years (dilution for shareholders). It spends 30% of revenue on research and development.

Score: 1.2 / 5

Value2/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)2.1
Forward P/E—
P/FCF—
P/S3.3
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-23.5%
Shareholder yield0.0%
Intrinsic value vs. price−82%

Growth and quality

Revenue growth (1 yr)-6.2%
Revenue growth (5 yrs, per year)-9.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-110.0%
ROIC (5-yr avg.)-154.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$84M$85M$91M$106M$98M$131M$138M$117M$113M$102M$104M
Net income$133M-$75M-$139M-$75M-$190M-$59M-$53M-$65M-$59M-$61M-$76M
Free cash flow-$66M-$83M-$152M-$46M-$93M-$57M-$28M-$38M-$26M-$26M-$44M
EPS (diluted)$0.34$-0.20$-0.52$-0.94$-2.43$-0.78$-0.74$-0.97$-1.49$-1.84$-2.62
Net margin157.6%-87.8%-152.6%-70.2%-194.1%-45.4%-38.4%-55.3%-52.2%-59.4%-72.8%
ROIC—-14.7%-20.0%—-540.4%-41.3%-27.8%-31.5%-64.2%-179.0%-130.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $1.35, 91% above the current price; targets range from $1.35 to $1.35; the consensus rating is “none”.

Frequently asked questions

What is Standard Biotools’s P/E ratio?

About 2.1, based on the last twelve months of diluted earnings per share.

Is Standard Biotools stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 82% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Standard Biotools pay a dividend?

Not currently.

Is Standard Biotools a good stock to buy?

We do not give buy or sell advice. Standard Biotools scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.